Published in Gut on March 28, 2007
Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut (2010) 1.59
Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne) (2015) 0.89
The interaction between insulin resistance, liver fibrosis and early virological response in Egyptian patients with chronic hepatitis C. Can J Gastroenterol (2012) 0.88
Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. Can J Gastroenterol (2009) 0.86
Trans fat feeding results in higher serum alanine aminotransferase and increased insulin resistance compared with a standard murine high-fat diet. Am J Physiol Gastrointest Liver Physiol (2009) 0.86
Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis. World J Gastroenterol (2014) 0.86
Hepatitis C Virus, Insulin Resistance, and Steatosis. J Clin Transl Hepatol (2016) 0.85
HCC development is associated to peripheral insulin resistance in a mouse model of NASH. PLoS One (2014) 0.81
Occlusion of portosystemic shunts improves hyperinsulinemia due to insulin resistance in cirrhotic patients with portal hypertension. J Gastroenterol (2013) 0.80
Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. Braz J Med Biol Res (2013) 0.79
Insulin Resistance is Associated With Significant Liver Fibrosis in Chronic Hepatitis C Patients: A Systemic Review and Meta-Analysis. J Clin Gastroenterol (2016) 0.76
Astragalus and Paeoniae Radix Rubra extract (APE) inhibits hepatic stellate cell activation by modulating transforming growth factor-β/Smad pathway. Mol Med Rep (2014) 0.75
Beta-cell glucose sensitivity in patients with liver fibrosis. Gut (2008) 0.75
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 109.13
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med (1998) 46.95
Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care (1999) 26.39
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol (1999) 14.07
Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab (2000) 11.97
2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens (2003) 11.32
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (2003) 9.36
Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care (2000) 9.10
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology (1999) 5.75
Assessment of insulin sensitivity in vivo. Endocr Rev (1985) 4.21
Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care (2000) 4.14
Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology (1999) 4.14
Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology (2003) 4.10
Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology (2004) 3.93
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology (2005) 3.47
A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care (2001) 3.07
Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol (2001) 2.81
Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology (2003) 2.53
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology (2004) 2.41
High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology (2001) 2.41
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut (2005) 2.39
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology (2006) 2.26
How to measure insulin sensitivity. J Hypertens (1998) 1.96
Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology (2006) 1.92
Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology (1999) 1.88
Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab (2005) 1.73
Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology (2002) 1.66
Chronic hepatitis: morphology and nomenclature. Mod Pathol (1994) 1.64
Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab (2003) 1.56
Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol (2005) 1.44
Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology (2001) 1.29
Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol (2003) 1.24
Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol (2005) 1.17
Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol (2005) 1.09
Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology (2006) 1.08
Insulin: in search of a syndrome. Diabet Med (2002) 1.05
Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. Eur J Clin Invest (2000) 1.03
Leptin and liver fibrosis: a matter of fat. Gastroenterology (2002) 1.01
Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. Dig Dis Sci (2002) 1.00
Insulin resistance and steatosis in hepatitis C virus infection. Gut (2005) 1.00
Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C. Am J Gastroenterol (2000) 0.94
Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-coinfected patients. J Viral Hepat (2006) 0.86
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes (2001) 9.67
Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med (1999) 5.65
delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A (1980) 5.12
Spk1/Rad53 is regulated by Mec1-dependent protein phosphorylation in DNA replication and damage checkpoint pathways. Genes Dev (1996) 4.98
Activation of Rad53 kinase in response to DNA damage and its effect in modulating phosphorylation of the lagging strand DNA polymerase. EMBO J (1999) 4.64
Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis (1980) 4.28
The delta agent. Hepatology (1983) 3.72
Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope. J Virol (1986) 3.63
Metformin in non-alcoholic steatohepatitis. Lancet (2001) 3.63
Types of 'reticulin' antibodies detected in human sera by immunofluorescence. J Clin Pathol (1973) 2.98
Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids. Biochim Biophys Acta (1980) 2.89
Delta hepatitis agent: structural and antigenic properties of the delta-associated particle. Infect Immun (1984) 2.81
Obstructive sleep apnea is associated with fatigue in multiple sclerosis. Mult Scler (2011) 2.77
The B subunit of the DNA polymerase alpha-primase complex in Saccharomyces cerevisiae executes an essential function at the initial stage of DNA replication. Mol Cell Biol (1994) 2.75
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood (2001) 2.71
Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia (2005) 2.67
bcl-2 expression in pleural and extrapleural solitary fibrous tumours. J Pathol (1997) 2.66
Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol (1973) 2.59
The hepatitis B virus-associated delta antigen: isolation from liver, development of solid-phase radioimmunoassays for delta antigen and anti-delta and partial characterization of delta antigen. J Immunol (1980) 2.57
Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis (2001) 2.56
Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther (2008) 2.50
Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia (2008) 2.32
Influence of delta infection on severity of hepatitis B. Lancet (1982) 2.31
Incidence and significance of antibodies to delta antigen in hepatitis B virus infection. Lancet (1979) 2.29
Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. J Intern Med (1993) 2.24
Epidemiology of HBV-associated delta agent: geographical distribution of anti-delta and prevalence in polytransfused HBsAg carriers. Lancet (1980) 2.17
Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med (1983) 2.16
Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol (2007) 2.12
A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med (1991) 2.10
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat (2011) 2.00
Efficacy of amoxycillin plus clavulanic acid-based triple therapy for Helicobacter pylori eradication: a retrospective study. Panminerva Med (2010) 1.99
Interferon-gamma release assays and childhood tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis (2011) 1.89
The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med (2004) 1.89
Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology (1999) 1.88
Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology (1996) 1.83
Molecular profile of human immunodeficiency virus type 1 infection in symptomless patients and in patients with AIDS. J Virol (1992) 1.80
Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology (1986) 1.75
The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. Dig Liver Dis (2004) 1.75
Epidemiology and microbiology of surgical wound infections. J Clin Microbiol (2000) 1.67
Hepatic disorders associated with liver-kidney microsomal antibodies. Br Med J (1974) 1.64
Disruption of the developmentally regulated Rev3l gene causes embryonic lethality. Curr Biol (2000) 1.63
The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol (2007) 1.62
Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev (2004) 1.62
Psychological status and depression in patients with liver cirrhosis. Dig Liver Dis (2005) 1.62
Safety of retroviral gene marking with a truncated NGF receptor. Nat Med (2003) 1.60
Inhibition of the NA(+)/H(+) exchanger reduces rat hepatic stellate cell activity and liver fibrosis: an in vitro and in vivo study. Gastroenterology (2001) 1.57
Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer (1996) 1.57
Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut (2008) 1.56
Fibrogenic effect of oxidative stress on rat hepatic stellate cells. Hepatology (1998) 1.55
Chronic Helicobacter pylori infection and migraine: a case-control study. Headache (2001) 1.54
Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial. Hepatology (1998) 1.53
Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol (1999) 1.52
Helicobacter pylori seroprevalence in cirrhotic patients with hepatitis B virus infection. Neth J Med (2000) 1.50
Characterization of the microsomal antigen related to a subclass of active chronic hepatitis. Immunology (1974) 1.50
Serological response to the hepatitis delta virus in hepatitis D. Lancet (1987) 1.50
Multicentre study of prevalence of HBV-associated delta infection and liver disease in drug-addicts. Lancet (1982) 1.50
Predicting outcomes and drug resistance with standardised treatment of active tuberculosis. Eur Respir J (2010) 1.49
Systemic nitric oxide production and renal function in nonazotemic human cirrhosis: a reappraisal. Am J Gastroenterol (2002) 1.49
Infection with the delta agent in chronic HBsAg carriers. Gastroenterology (1981) 1.48
Incidence of hepatitis delta virus infection in acute HBsAg-negative hepatitis. J Infect Dis (1989) 1.48
Epidemiologic patterns of infection with the hepatitis B virus-associated delta agent in Italy. Am J Epidemiol (1983) 1.47
Zinc supplementation improves glucose disposal in patients with cirrhosis. Metabolism (1998) 1.47
Enzyme-linked immunosorbent assay for detection of antibody to the hepatitis B surface antigen-associated delta antigen. J Clin Microbiol (1981) 1.47
PIK1, an essential phosphatidylinositol 4-kinase associated with the yeast nucleus. EMBO J (1994) 1.45
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis (2010) 1.45
Comprehensive drug screening in decision making of patients attending the emergency department for suspected drug overdose. Emerg Med J (2003) 1.44
Anti-human versus anti-guinea pig tissue transglutaminase antibodies as the first-level serological screening test for coeliac disease in the general population. Dig Liver Dis (2004) 1.43
Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. J Hepatol (2001) 1.43
Acute carbon tetrachloride feeding induces damage of large but not small cholangiocytes from BDL rat liver. Am J Physiol (1999) 1.42
Monoethyl glycine xylidide (MEGX) test evaluation in primary biliary cirrhosis: comparison with Mayo score. Eur J Gastroenterol Hepatol (1997) 1.42
Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des (2010) 1.41
Primary biliary cirrhosis: modalities of injury and death in biliary epithelium. Dig Liver Dis (2001) 1.40
Efficacy of azythromicin-based triple therapy for Helicobacter pylori infection: a retrospective study. Panminerva Med (2008) 1.39
Cholinergic system modulates growth, apoptosis, and secretion of cholangiocytes from bile duct-ligated rats. Gastroenterology (1999) 1.39
Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis (2002) 1.39
Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans. Mycopathologia (1993) 1.38
Radioimmunoassay detection of IgM antibodies to the HBV-associated delta (delta) antigen:" clinical significance in delta infection. J Med Virol (1982) 1.38
Microcolony culture techniques for tuberculosis diagnosis: a systematic review. Int J Tuberc Lung Dis (2011) 1.35
Intracellular signaling pathways involved in acetaldehyde-induced collagen and fibronectin gene expression in human hepatic stellate cells. Hepatology (2001) 1.34
Chronic hepatitis D: a vanishing Disease? An Italian multicenter study. Hepatology (2000) 1.34
Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis (2006) 1.34
Ribosomal antibodies detected by immunofluorescence in systemic lupus erythematosus and other collagenoses. Clin Exp Immunol (1974) 1.33
Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Ther (2007) 1.31
The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol (2012) 1.30
Complexity of attrition in the treatment of obesity: clues from a structured telephone interview. Int J Obes (Lond) (2006) 1.29
Modulation of Ca2+ influx dependent on store depletion by intracellular adenine-guanine nucleotide levels. J Biol Chem (1994) 1.29
Intrahepatic localization of the surface (HBsAg) and core (HBcAg) antigenic determinants associated with hepatitis B virus in biopsy samples from patients with liver disease. Ric Clin Lab (1976) 1.27
A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. J Hepatol (1990) 1.24
Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia. Am J Pathol (1998) 1.24
Global tuberculosis trends: a reflection of changes in tuberculosis control or in population health? Int J Tuberc Lung Dis (2009) 1.23
Complement fixing hepatitis B core antigen immune complexes in the liver of patients with HBs antigen positive chronic disease. Gut (1976) 1.23
The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol (2011) 1.23